Terms: = Germ cell tumor AND EGFR, mENA, 1956, ENSG00000146648, P00533, ERBB1, ERBB AND Treatment
1308 results:
1. Phase II Study of Osimertinib in Patients With Epidermal Growth Factor Receptor Mutations: Results From the NCI-MATCH ECOG-ACRIN (EAY131) Trial Subprotocol E.
Chen MF; Song Z; Yu HA; Sequist LV; Lovly CM; Mitchell EP; Moscow JA; Gray RJ; Wang V; McShane LM; Rubinstein LV; Patton DR; Williams PM; Hamilton SR; Umemura Y; Tricoli JV; Conley BA; Arteaga CL; Harris LN; O'Dwyer PJ; Chen AP; Flaherty KT
JCO Precis Oncol; 2024 Apr; 8():e2300454. PubMed ID: 38591867
[TBL] [Abstract] [Full Text] [Related]
2. Exploring ncRNA-mediated regulation of egfr signalling in glioblastoma: From mechanisms to therapeutics.
Thapa R; Afzal M; Goyal A; Gupta G; Bhat AA; Almalki WH; Kazmi I; Alzarea SI; Shahwan M; Kukreti N; Ali H; Dureja H; Kumar P; Singh TG; Kuppusamy G; Singh SK; Dua K
Life Sci; 2024 May; 345():122613. PubMed ID: 38582393
[TBL] [Abstract] [Full Text] [Related]
3. Quantifying intra-tumoral genetic heterogeneity of glioblastoma toward precision medicine using MRI and a data-inclusive machine learning algorithm.
Wang L; Wang H; D'Angelo F; Curtin L; Sereduk CP; Leon G; Singleton KW; Urcuyo J; Hawkins-Daarud A; Jackson PR; Krishna C; Zimmerman RS; Patra DP; Bendok BR; Smith KA; Nakaji P; Donev K; Baxter LC; Mrugała MM; Ceccarelli M; Iavarone A; Swanson KR; Tran NL; Hu LS; Li J
PLoS One; 2024; 19(4):e0299267. PubMed ID: 38568950
[TBL] [Abstract] [Full Text] [Related]
4. Targeting the egfr pathway: An alternative strategy for the treatment of tuberous sclerosis complex?
Schachenhofer J; Gruber VE; Fehrer SV; Haider C; Glatter S; Liszewska E; Höftberger R; Aronica E; Rössler K; Jaworski J; Scholl T; Feucht M
Neuropathol Appl Neurobiol; 2024 Apr; 50(2):e12974. PubMed ID: 38562027
[TBL] [Abstract] [Full Text] [Related]
5. Comprehensive mutational scanning of egfr reveals TKI sensitivities of extracellular domain mutants.
Hayes TK; Aquilanti E; Persky NS; Yang X; Kim EE; Brenan L; Goodale AB; Alan D; Sharpe T; Shue RE; Westlake L; Golomb L; Silverman BR; Morris MD; Fisher TR; Beyene E; Li YY; Cherniack AD; Piccioni F; Hicks JK; Chi AS; Cahill DP; Dietrich J; Batchelor TT; Root DE; Johannessen CM; Meyerson M
Nat Commun; 2024 Mar; 15(1):2742. PubMed ID: 38548752
[TBL] [Abstract] [Full Text] [Related]
6. Integrative multi-omics characterization reveals sex differences in glioblastoma.
Jang B; Yoon D; Lee JY; Kim J; Hong J; Koo H; Sa JK
Biol Sex Differ; 2024 Mar; 15(1):23. PubMed ID: 38491408
[TBL] [Abstract] [Full Text] [Related]
7. Intraventricular CARv3-TEAM-E T cells in Recurrent Glioblastoma.
Choi BD; Gerstner ER; Frigault MJ; Leick MB; Mount CW; Balaj L; Nikiforow S; Carter BS; Curry WT; Gallagher K; Maus MV
N Engl J Med; 2024 Apr; 390(14):1290-1298. PubMed ID: 38477966
[TBL] [Abstract] [Full Text] [Related]
8. Thyroid dysfunction after immune checkpoint inhibitors in a single-centre UK pan-cancer cohort: A retrospective study.
Kennedy OJ; Ali N; Lee R; Monaghan P; Adam S; Cooksley T; Lorigan P
Eur J Cancer; 2024 May; 202():113949. PubMed ID: 38432099
[TBL] [Abstract] [Full Text] [Related]
9. AGCM-22, a novel cetuximab-based egfr-targeting antibody-drug-conjugate with highly selective anti-glioblastoma efficacy.
Li D; Sun X; Li Y; Shang C; Dong Y; Zhao R; Zhang H; Wang Z; Fan S; Ma C; Li X
Bioorg Med Chem; 2024 Mar; 102():117657. PubMed ID: 38428068
[TBL] [Abstract] [Full Text] [Related]
10. Epidermal Growth Factor Receptor Inhibitors in Glioblastoma: Current Status and Future Possibilities.
Ezzati S; Salib S; Balasubramaniam M; Aboud O
Int J Mol Sci; 2024 Feb; 25(4):. PubMed ID: 38396993
[TBL] [Abstract] [Full Text] [Related]
11. Signaling Pathways of AXL Receptor Tyrosine Kinase Contribute to the Pathogenetic Mechanisms of Glioblastoma.
Repici A; Ardizzone A; De Luca F; Colarossi L; Prestifilippo A; Pizzino G; Paterniti I; Esposito E; Capra AP
Cells; 2024 Feb; 13(4):. PubMed ID: 38391974
[TBL] [Abstract] [Full Text] [Related]
12. Exploring the therapeutic mechanisms and prognostic targets of Biochanin A in glioblastoma via integrated computational analysis and in vitro experiments.
Ge W; Yuan G; Wang D; Dong L
Sci Rep; 2024 Feb; 14(1):3783. PubMed ID: 38360888
[TBL] [Abstract] [Full Text] [Related]
13. Targeted delivery of polo-like kinase 1 siRNA nanoparticles using an egfr-PEG bispecific antibody inhibits proliferation of high-risk neuroblastoma.
Logan A; Howard CB; Huda P; Kimpton K; Ma Z; Thurecht KJ; McCarroll JA; Moles E; Kavallaris M
J Control Release; 2024 Mar; 367():806-820. PubMed ID: 38341177
[TBL] [Abstract] [Full Text] [Related]
14. treatment outcome of IDH1/2 wildtype CNS WHO grade 4 glioma histologically diagnosed as WHO grade II or III astrocytomas.
Keric N; Krenzlin H; Kalasauskas D; Freyschlag CF; Schnell O; Misch M; von der Brelie C; Gempt J; Krigers A; Wagner A; Lange F; Mielke D; Sommer C; Brockmann MA; Meyer B; Rohde V; Vajkoczy P; Beck J; Thomé C; Ringel F
J Neurooncol; 2024 Mar; 167(1):133-144. PubMed ID: 38326661
[TBL] [Abstract] [Full Text] [Related]
15. Expression of molecular markers and synergistic anticancer effects of chemotherapy with antimicrobial peptides on glioblastoma cells.
Chernov AN; Kim AV; Skliar SS; Fedorov EV; Tsapieva AN; Filatenkova TA; Chutko AL; Matsko MV; Galimova ES; Shamova OV
Cancer Chemother Pharmacol; 2024 May; 93(5):455-469. PubMed ID: 38280033
[TBL] [Abstract] [Full Text] [Related]
16. GlioPredictor: a deep learning model for identification of high-risk adult IDH-mutant glioma towards adjuvant treatment planning.
Zheng S; Rammohan N; Sita T; Teo PT; Wu Y; Lesniak M; Sachdev S; Thomas TO
Sci Rep; 2024 Jan; 14(1):2126. PubMed ID: 38267516
[TBL] [Abstract] [Full Text] [Related]
17. nSEA: n-Node Subnetwork Enumeration Algorithm Identifies Lower Grade Glioma Subtypes with Altered Subnetworks and Distinct Prognostics.
Zhang Z; Wang C; Zhao Z; Yi Z; Durmaz A; Yu JS; Bebek G
Pac Symp Biocomput; 2024; 29():521-533. PubMed ID: 38160304
[TBL] [Abstract] [Full Text] [Related]
18. A network pharmacology- and transcriptomics-based investigation reveals an inhibitory role of β-sitosterol in glioma via the egfr/MAPK signaling pathway.
Xie Y; Chen Z; Li S; Yan M; He W; Li L; Si J; Wang Y; Li X; Ma K
Acta Biochim Biophys Sin (Shanghai); 2024 Feb; 56(2):223-238. PubMed ID: 38143380
[TBL] [Abstract] [Full Text] [Related]
19. Dual blockade of egfr and PI3K signaling pathways offers a therapeutic strategy for glioblastoma.
Guo T; Wu C; Zhang J; Yu J; Li G; Jiang H; Zhang X; Yu R; Liu X
Cell Commun Signal; 2023 Dec; 21(1):363. PubMed ID: 38115126
[TBL] [Abstract] [Full Text] [Related]
20. Druggable growth dependencies and tumor evolution analysis in patient-derived organoids of neuroendocrine neoplasms from multiple body sites.
Dayton TL; Alcala N; Moonen L; den Hartigh L; Geurts V; Mangiante L; Lap L; Dost AFM; Beumer J; Levy S; van Leeuwaarde RS; Hackeng WM; Samsom K; Voegele C; Sexton-Oates A; Begthel H; Korving J; Hillen L; Brosens LAA; Lantuejoul S; Jaksani S; Kok NFM; Hartemink KJ; Klomp HM; Borel Rinkes IHM; Dingemans AM; Valk GD; Vriens MR; Buikhuisen W; van den Berg J; Tesselaar M; Derks J; Speel EJ; Foll M; Fernández-Cuesta L; Clevers H
Cancer Cell; 2023 Dec; 41(12):2083-2099.e9. PubMed ID: 38086335
[TBL] [Abstract] [Full Text] [Related]
[Next]
